4 Stocks Pushing The Health Services Industry Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 14 points (-0.1%) at 15,098 as of Friday, Aug. 16, 2013, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,393 issues advancing vs. 1,555 declining with 92 unchanged.

The Health Services industry currently sits down 0.6% versus the S&P 500, which is down 0.1%. On the negative front, top decliners within the industry include Edwards Life ( EW), down 2.0%, CareFusion ( CFN), down 1.1%, St Jude Medical ( STJ), down 1.1%, DaVita HealthCare Partners ( DVA), down 1.0% and Waters Corporation ( WAT), down 1.0%. Top gainers within the industry include Parexel International Corporation ( PRXL), up 2.7%, Boston Scientific ( BSX), up 1.6%, Cigna ( CI), up 1.4% and Aetna ( AET), up 0.9%.

TheStreet would like to highlight 4 stocks pushing the industry lower today:

4. C.R. Bard ( BCR) is one of the companies pushing the Health Services industry lower today. As of noon trading, C.R. Bard is down $1.89 (-1.7%) to $111.58 on heavy volume. Thus far, 417,193 shares of C.R. Bard exchanged hands as compared to its average daily volume of 541,200 shares. The stock has ranged in price between $111.24-$113.13 after having opened the day at $112.27 as compared to the previous trading day's close of $113.47.

C. R. Bard, Inc. designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. C.R. Bard has a market cap of $9.1 billion and is part of the health care sector. Shares are up 16.1% year to date as of the close of trading on Thursday. Currently there are 5 analysts that rate C.R. Bard a buy, 1 analyst rates it a sell, and 12 rate it a hold.

TheStreet Ratings rates C.R. Bard as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share. Get the full C.R. Bard Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Community Health Systems ( CYH) is down $0.86 (-2.0%) to $41.03 on average volume. Thus far, 852,710 shares of Community Health Systems exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $40.68-$41.78 after having opened the day at $41.68 as compared to the previous trading day's close of $41.89.

Community Health Systems, Inc., together with its subsidiaries, provides general and specialized hospital healthcare services to patients in the United States. Community Health Systems has a market cap of $4.1 billion and is part of the health care sector. Shares are up 36.3% year to date as of the close of trading on Thursday. Currently there are 10 analysts that rate Community Health Systems a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Community Health Systems as a buy. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Community Health Systems Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Covidien ( COV) is down $0.61 (-1.0%) to $61.24 on average volume. Thus far, 1.2 million shares of Covidien exchanged hands as compared to its average daily volume of 2.6 million shares. The stock has ranged in price between $61.13-$61.75 after having opened the day at $61.58 as compared to the previous trading day's close of $61.85.

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. Covidien has a market cap of $29.1 billion and is part of the health care sector. Shares are up 7.1% year to date as of the close of trading on Thursday. Currently there are 13 analysts that rate Covidien a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Covidien as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures, notable return on equity and increase in stock price during the past year. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Covidien Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Baxter International ( BAX) is down $0.82 (-1.1%) to $71.51 on average volume. Thus far, 1.6 million shares of Baxter International exchanged hands as compared to its average daily volume of 2.9 million shares. The stock has ranged in price between $71.33-$72.09 after having opened the day at $72.00 as compared to the previous trading day's close of $72.33.

Baxter International Inc., through its subsidiaries, develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. Baxter International has a market cap of $39.9 billion and is part of the health care sector. Shares are up 8.5% year to date as of the close of trading on Thursday. Currently there are 12 analysts that rate Baxter International a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Baxter International as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Baxter International Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).
null

If you liked this article you might like

EY's Greene Sees More Med Tech, CRO Deals Ahead

EY's Greene Sees More Med Tech, CRO Deals Ahead

Deals of the Week: Waiting for Clarity

Deals of the Week: Waiting for Clarity

Merger Buzz Drives Akorn to Top of Health Chart in April

Merger Buzz Drives Akorn to Top of Health Chart in April

Deals of the Week: Reason for Optimism

Deals of the Week: Reason for Optimism

Good Medicine Makes for 3 Good Charts

Good Medicine Makes for 3 Good Charts